E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
A life-threatening fungal infection caused by Aspergillus species in patients with suppressed immune systems; Invasive Aspergillosis primarily affects lungs, causing fever, cough, shortness of breath |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051597 |
E.1.2 | Term | Cerebral aspergillosis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006473 |
E.1.2 | Term | Bronchopulmonary aspergillosis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003490 |
E.1.2 | Term | Aspergillosis pharyngeal |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10022881 |
E.1.2 | Term | Invasive bronchopulmonary aspergillosis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059259 |
E.1.2 | Term | Pulmonary aspergillosis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003488 |
E.1.2 | Term | Aspergillosis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate that treatment with VL-2397 is non-inferior to standard
treatment (voriconazole (with TDM), isavuconazole, or liposomal
amphotericin) in the comparison of ACM at 4 weeks in immunocompromised adults with possible, probable, or proven IA. |
|
E.2.2 | Secondary objectives of the trial |
To demonstrate that treatment with VL-2397 for 28 days followed by
voriconazole, isavuconazole, or liposomal amphotericin B is non-inferior
to Standard Treatment in the comparison of ACM at 6 weeks in immunocompromised adults
with possible, probable, or proven IA.
To provide supportive information for the primary and key secondary
endpoints and to provide further information on potential uses and
benefits of VL-2397.
To analyze the full (intensive) PK profile of VL-2397 in at least 10
participants; to analyze sparse PK from all other participants. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For inclusion into the VL2397-201 study, participants must meet all of the following criteria:
1. Male or female (non-pregnant) participants, ≥ age 18 years at the time of consent, and hospitalized at randomization; women of childbearing potential must have a negative serum pregnancy test during screening
2. New diagnosis of possible, probable, or proven pulmonary (or sinopulmonary) IA as defined by the 2008 EORTC/MSG criteria with at least one of the following host factors:
Acute leukemia (AML or ALL) or other hematological condition (chronic leukemia, myelodysplastic syndrome, multiple myeloma, or aplastic anemia) with severe neutropenia temporally related to the onset of IA
Allogeneic HCT recipient
Hematological condition (acute or chronic leukemia, myelodysplastic syndrome, multiple myeloma, or aplastic anemia), lymphoma, solid organ transplant or autologous HCT recipient receiving immunosuppressive therapy. Note: Immunosuppressive therapy is recent use of corticosteroids (at a mean minimum dose of 0.3 mg/kg/day of prednisone or equivalent for > 3 weeks) or other immunosuppressants such as calcineurin inhibitors, TNF-α blockers, T-cell-specific monoclonal antibodies, or nucleoside analogs.
3. Able to provide informed consent and willing to comply with the study requirements |
|
E.4 | Principal exclusion criteria |
Potential participants will be excluded from the study if any of the following criteria are met:
1. Respiratory failure on mechanical ventilation
2. Refractory or relapsed leukemia unlikely to respond to reinduction chemotherapy (unless the participant is an allo-HCT recipient)
3. Severe neutropenia (absolute neutrophil count < 500/μL ) for > 10 days that is unlikely to recover during the study
4. Unlikely to survive 30 days after first dose of Study Drug due to graft failure, severe (grade 4) acute graft-versus-host disease (GvHD), refractory chronic GvHD, or other life-threatening condition
5. IA (proven or suspected) involving sites other than lungs and sinuses, including central nervous system (CNS), skin, or liver, and/or disseminated disease
6. Suspected or proven infection with Candida krusei
7. Systemic infection with a bacterial or viral pathogen that is not under control or cannot be treated, or systemic infection with a fungal pathogen other than Aspergillus. Note: Uncomplicated bacteremia, uncomplicated urinary tract infection, and CMV viremia without end organ disease are allowed.
8. Uncontrolled diabetes (given the inherent higher risk for mucormycosis), unless the diagnosis is proven or probable IA
9. Recent episode of acute IA not responding to treatment, chronic aspergillosis, aspergilloma in pre-existing cavity, or allergic aspergillosis
10. Receipt of > 4 cumulative days of systemic antifungal treatment for IA within 7 days prior to study entry. Note: Recent or prior use of a mold-active antifungal for prophylaxis, as determined by the Investigator, is allowed.
11. Hepatic dysfunction, defined as any one of the following: total bilirubin ≥ 3 x the upper limit of normal (ULN), alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 5 x ULN, cirrhosis, or chronic hepatic failure
12. Moderate to severe renal dysfunction defined as any one of the following: creatinine clearance < 50 mL/min at screening, currently on dialysis, or likely to require dialysis during administration of Study Drug
13. Treatment with any investigational drug in a clinical trial within 14 days prior to the first dose of Study Drug
14. Any known or suspected condition of the potential participant that could jeopardize participant adherence to study requirements or impede the accurate assessments of efficacy
15. Males and females of childbearing potential who are unwilling to use highly effective contraceptive methods throughout the study
16. Pregnant or breastfeeding females
17. Alcohol intolerance or dependence (alcoholism)
18. Epilepsy that may be exacerbated by alcohol intake |
|
E.5 End points |
E.5.1 | Primary end point(s) |
ACM at 4 weeks in the ITT population |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
ACM at 6 weeks in the ITT Population.
To provide supportive information for the primary and key secondary endpoints and to provide further information on potential uses and benefits of VL-2397 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
France |
Germany |
Korea, Republic of |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |